FDA OK's Ozempic To Protect Kidneys in Type 2 Diabetes Patients
By India Edwards HealthDay Reporter
WEDNESDAY, Jan. 29, 2025 -- A popular diabetes drug just got a major new approval -- and it could be a game-changer for millions of Americans at risk for kidney failure.
The U.S. Food and Drug Administration (FDA) has officially approved Ozempic to help reduce the risk of serious kidney complications in people with Type 2 diabetes and chronic kidney disease.
Type 2 diabetes is a leading cause of chronic kidney disease, which affects more than 1 in 7 U.S. adults. The new approval allows doctors to prescribe Ozempic specifically to lower the risk of kidney failure, dialysis and death from heart-related problems in these high-risk patients.
“Over the last 20 years, it’s been an area where researchers tried hard but delivered very little,” Dr. Stephen Gough, senior vice president of global medical affairs at Novo Nordisk, the company that makes Ozempic, told The New York Times. “To have something new like this is really exciting, and offers promise to patients.”
Doctors already use Ozempic to manage Type 2 diabetes and reduce the risk of heart disease in diabetic patients. This move, as reported by The Times, was based on research showing that people with both Type 2 diabetes and chronic kidney disease who took Ozempic had a 24% lower risk of kidney-related complications, such as needing dialysis or an organ transplant.
Patients in the study also had slower rates of kidney decline and were less likely to die from heart problems.
“The more we can delay the decline in kidney function, the better,” Dr. Melanie Hoenig, a kidney specialist at Beth Israel Deaconess Medical Center in Boston, told The Times.
Ozempic is often referred to as a "weight loss" drug, but it is not officially approved for that purpose. It is mainly used to control blood sugar, but researchers suspect the drug may also reduce inflammation in the kidneys and throughout the body.
Doctors often prescribe medications to lower blood pressure, blood sugar and cholesterol to help protect the kidneys, but treatment options are still limited.
With Ozempic’s approval for kidney disease, though, demand for the drug is expected to grow, and Novo Nordisk has already struggled to keep up.
What's more, the FDA lists semaglutide, the compound in Ozempic and the weight loss drug Wegovy, as currently in shortage.
“Many people, unfortunately, cannot get it,” Hoenig told The Times. “But if they can and it works for them, and they can tolerate it, it’s a wonderful thing to have more tools.”
Sources
- The New York Times, media report, Jan. 28, 2025: U.S. Food and Drug Administration, drug shortage database
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
Belly Fat, Diabetes and Drinking Doubles Liver Disease Risk
THURSDAY, Feb. 13, 2025 -- If you've got a big belly, diabetes or high blood pressure, you may want to limit your alcohol, experts warn, as drinking could significantly raise your...
Senators Call on FDA to Act Against Misleading Weight-Loss Drug Commercials
WEDNESDAY, Feb. 12, 2025 -- Commercials run by the telehealth company Hims & Hers have been placed under the microscope as lawmakers are calling out advertisement of...
More Evidence Ozempic Can Curb Alcoholism
WEDNESDAY, Feb. 12, 2025 -- Yet another study is supporting the notion that the blockbuster GLP-1 drug Ozempic can help problems drinkers curb their intake. The research found...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.